Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) insider Leger Tina Amber St sold 1,000 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. The trade was a 47.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Immunocore Trading Down 1.5%

Shares of IMCR stock opened at $32.68 on Friday. The stock has a market cap of $1.65 billion, a P/E ratio of -57.33 and a beta of 0.78. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $23.15 and a 1 year high of $40.71. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. The stock has a 50 day simple moving average of $33.81 and a 200 day simple moving average of $34.30.

Hedge Funds Weigh In On Immunocore

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada boosted its position in Immunocore by 45.1% in the first quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after buying an additional 13,689 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Immunocore by 4,696.3% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after acquiring an additional 1,268 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in shares of Immunocore during the 2nd quarter valued at $292,000. Y Intercept Hong Kong Ltd bought a new stake in Immunocore during the 2nd quarter worth $1,621,000. Finally, Assetmark Inc. increased its holdings in Immunocore by 3.7% in the 2nd quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock worth $1,097,000 after purchasing an additional 1,248 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst and institutional support: multiple brokers still carry buy/overweight views and the consensus average price target (~$60.90) sits well above the current market level, which can underpin upside if clinical or commercial progress resumes. MarketBeat IMCR Coverage
• Positive Sentiment: High institutional ownership (~84.5%): large, stable holders (Primecap, Bellevue, Tang Capital, Millennium, Armistice) can reduce free float and provide support over the medium term as long-term investors remain committed. MarketBeat IMCR Coverage
• Neutral Sentiment: Strong liquidity on the balance sheet: very high current and quick ratios (~6.0) reduce short-term solvency risk but are unlikely to drive near-term share moves absent new catalysts.
• Neutral Sentiment: Short-interest data appears inconsistent: the recent report shows effectively 0 shares short (and 0 days to cover), which is likely a reporting anomaly and should be treated cautiously rather than interpreted as a market signal.
• Neutral Sentiment: Lower-than-average intraday volume can amplify price moves on either positive or negative news; monitor volume for conviction on any follow-through.
• Negative Sentiment: Clustered insider selling: CEO Bahija Jallal sold 11,474 shares (~48% reduction in her stake) and several other senior insiders (David Berman, John Goll, Tina Leger) also sold large portions on the same day—a development that commonly pressures sentiment and can trigger short‑term selling. InsiderTrades: CEO Sells IMCR SEC Form 4 (Berman)

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Morgan Stanley upped their price objective on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Wells Fargo & Company started coverage on shares of Immunocore in a report on Friday, October 31st. They set an “overweight” rating and a $60.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Wednesday, February 4th. Finally, UBS Group set a $55.00 target price on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immunocore has a consensus rating of “Moderate Buy” and a consensus target price of $60.90.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.